rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLCrpcardio-1462Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯDrug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cellsЛекарственные взаимодействия новых пероральных антикоагулянтов: внутри и вне ячеек таблицыhttps://orcid.org/0000-0002-0831-6320БельдиевСергей НиколаевичBel'dievSergey Nikolaevich

Кафедра внутренних болезней факультета дополнительного профессионального образования, доцент, SPIN-код 3313-6347

Faculty of Postgraduate Studies, Chair of Internal Medicine, Associate Professor

sbeldiev@yandex.ruМедведеваИрина ВладимировнаMedvedevaIrina Vladimirovna

Кафедра внутренних болезней факультета дополнительного профессионального образования, доцент

Faculty of Postgraduate Studies, Chair of Internal Medicine, Associate Professor

irinavlmed@yandex.ruПлатоновДмитрий ЮрьевичPlatonovDmitry Jur'evich

Кафедра внутренних болезней факультета дополнительного профессионального образования, зав. кафедрой

Faculty of Postgraduate Studies, Chair of Internal Medicine, Associate Professor, Head of Chair of Internal Medicine

diplato64@mail.ruТверской государственный медицинский университетРоссияTver State Medical UniversityRussian Federation2017301020171351462Copyright © Bel'diev S.N., Medvedeva I.V., Platonov D.J., 20172017Бельдиев С.Н., Медведева И.В., Платонов Д.Ю.Bel'diev S.N., Medvedeva I.V., Platonov D.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1462

The opinion is expressed in some domestic publications that rivaroxaban has the most favorable profile of drug interaction in comparison to other non-vitamin K antagonist oral anticoagulants (NOAC). The basis for such judgments is the summary table of drug interaction from the 2015 practical guide of the European Heart Rhythm Association on the use of NOAC in patients with non-valvular atrial fibrillation.

В некоторых отечественных публикациях высказывается мнение о том, что ривароксабан обладает наиболее благоприятным профилем лекарственного взаимодействия по сравнению с другими новыми оральными антикоагулянтами (НОАК). Основой для подобных суждений стала сводная таблица лекарственных взаимодействий НОАК из рекомендаций Европейской ассоциации сердечного ритма 2015 года по применению НОАК у пациентов с неклапанной фибрилляцией предсердий.

дабигатранапиксабанривароксабанэдоксабанлекарственные взаимодействияdabigatranapixabanrivaroxabanedoxabandrug interactionsReferencesBunin Y.A., Miklishanskaya S.V. Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Ration Pharmacother Cardiol. 2016;12(4):465-70. (In Russian) [Бунин Ю.А., Миклишанская С.В. Клиническое значение новых пероральных антикоагулянтов в профилактике тромбоэмболических осложнений у больных с фибрилляцией предсердий: не все мечты сбываются. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):465-70]. doi:10.20996/1819-6446-2016-12-4-465-470.Bunin Y.A., Miklishanskaya S.V. Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Ration Pharmacother Cardiol. 2016;12(4):465-70. (In Russian) [Бунин Ю.А., Миклишанская С.В. Клиническое значение новых пероральных антикоагулянтов в профилактике тромбоэмболических осложнений у больных с фибрилляцией предсердий: не все мечты сбываются. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):465-70]. doi:10.20996/1819-6446-2016-12-4-465-470.Sychev D.A., Mirzaev K.B., Levanov A.N. Drug interactions of new oral anticoagulants: View of a clinical pharmacologist. Russian Heart Journal. 2016;15(5):335-41. (In Russian) [Сычев Д.А., Мирзаев К.Б., Леванов А.Н. Межлекарственные взаимодействия новых пероральных антикоагулянтов: взгляд клинического фармаколога. Сердце: журнал для практикующих врачей. 2016;15 (5):335-341]. doi: 10.18087/rhj.2016.5.2220.Sychev D.A., Mirzaev K.B., Levanov A.N. Drug interactions of new oral anticoagulants: View of a clinical pharmacologist. Russian Heart Journal. 2016;15(5):335-41. (In Russian) [Сычев Д.А., Мирзаев К.Б., Леванов А.Н. Межлекарственные взаимодействия новых пероральных антикоагулянтов: взгляд клинического фармаколога. Сердце: журнал для практикующих врачей. 2016;15 (5):335-341]. doi: 10.18087/rhj.2016.5.2220.Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51. doi: 10.1093/europace/eut083.Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51. doi: 10.1093/europace/eut083.Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi: 10.1093/europace/euv309.Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi: 10.1093/europace/euv309.Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838-46. doi: 10.1111/bcp.12541.Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838-46. doi: 10.1111/bcp.12541.Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/bcp.12075.Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/bcp.12075.Moore KT, Vaidyanathan S, Natarajan J, et al. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol. 2014;54(12):1407-20. doi: 10.1002/jcph.352.Moore KT, Vaidyanathan S, Natarajan J, et al. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol. 2014;54(12):1407-20. doi: 10.1002/jcph.352.Grillo JA, Zhao P, Bullock J, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos. 2012;33(2):99-110. doi: 10.1002/bdd.1771.Grillo JA, Zhao P, Bullock J, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos. 2012;33(2):99-110. doi: 10.1002/bdd.1771.Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331-42. doi: 10.1007/s40256-013-0029-0.Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331-42. doi: 10.1007/s40256-013-0029-0.Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): Clinical pharmacology and biopharmaceutics review(s). Application number 22-512. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf. Accessed by June 05, 2017.Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): Clinical pharmacology and biopharmaceutics review(s). Application number 22-512. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf. Accessed by June 05, 2017.Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi: 10.1111/j.1538-7836.2011.04498.x.Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi: 10.1111/j.1538-7836.2011.04498.x.Cheong EJY, Goh JJN, Hong Y, et al. Application of static modeling in the prediction of in vivo drug-drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies. Drug Metabolism and Disposition. 2017;45(3):260-8. doi:10.1124/dmd.116.073890.Cheong EJY, Goh JJN, Hong Y, et al. Application of static modeling in the prediction of in vivo drug-drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies. Drug Metabolism and Disposition. 2017;45(3):260-8. doi:10.1124/dmd.116.073890.Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053-62. doi: 10.1111/j.1365-2125.2012.04453.x.Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053-62. doi: 10.1111/j.1365-2125.2012.04453.x.European Medicines Agency. Pradaxa (dabigatran etexilate): summary of product characteristics. Date of the latest renewal: 17 January 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed by June 05, 2017.European Medicines Agency. Pradaxa (dabigatran etexilate): summary of product characteristics. Date of the latest renewal: 17 January 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed by June 05, 2017.Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. 2012;52(2):243-50. doi: 10.1177/0091270010393342.Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. 2012;52(2):243-50. doi: 10.1177/0091270010393342.Frost C, Song Y, Yu Z, et al. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol. 2017;9:19-28. doi: 10.2147/CPAA.S115687.Frost C, Song Y, Yu Z, et al. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol. 2017;9:19-28. doi: 10.2147/CPAA.S115687.Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban – an oral, direct Factor Xa inhibitor – and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40(5):1688-707. DOI: 10.1177/030006051204000508.Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban – an oral, direct Factor Xa inhibitor – and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40(5):1688-707. DOI: 10.1177/030006051204000508.Bachmakov I, Werner U, Endress B, et al. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006;20(3):273-82. doi: 10.1111/j.1472-8206.2006.00408.x.Bachmakov I, Werner U, Endress B, et al. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006;20(3):273-82. doi: 10.1111/j.1472-8206.2006.00408.x.Shulkin A.V., Yakusheva E.N., Popova N.M. The role of P-glycoprotein in rational pharmacotherapy in cardiology. Ration Pharmacother Cardiol. 2013;9(6):701-7. (In Russian) [Щулькин А.В., Якушева Е.Н., Попова Н.М. Роль гликопротеина-Р в рациональной фармакотерапии в кардиологии. Рациональная Фармакотерапия в Кардиологии. 2013;9(6):701-7]. doi:10.20996/1819-6446-2013-9-6-701-707.Shulkin A.V., Yakusheva E.N., Popova N.M. The role of P-glycoprotein in rational pharmacotherapy in cardiology. Ration Pharmacother Cardiol. 2013;9(6):701-7. (In Russian) [Щулькин А.В., Якушева Е.Н., Попова Н.М. Роль гликопротеина-Р в рациональной фармакотерапии в кардиологии. Рациональная Фармакотерапия в Кардиологии. 2013;9(6):701-7]. doi:10.20996/1819-6446-2013-9-6-701-707.Stangier J, Rathgen K, Stähle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9(1):59-68. doi: 10.2165/00129784-200909010-00006.Stangier J, Rathgen K, Stähle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9(1):59-68. doi: 10.2165/00129784-200909010-00006.Parasrampuria DA, Mendell J, Shi M, et al. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82(6):1591-1600. doi: 10.1111/bcp.13092.Parasrampuria DA, Mendell J, Shi M, et al. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82(6):1591-1600. doi: 10.1111/bcp.13092.Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-283. doi: 10.1111/jth.13577.Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-283. doi: 10.1111/jth.13577.Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74(3):490-500. doi: 10.1111/j.1365-2125.2012.04218.x.Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74(3):490-500. doi: 10.1111/j.1365-2125.2012.04218.x.Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119-27. doi: 10.1007/s40256-015-0157-9.Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119-27. doi: 10.1007/s40256-015-0157-9.Therapeutic Goods Administration of Australian Government Department of Health and Ageing. Australian public assessment report for rivaroxaban. September 2012. Available at: www.tga.gov.au/sites/default/files/auspar-rivaroxaban-120913.pdf. Accessed by June 05, 2017.Therapeutic Goods Administration of Australian Government Department of Health and Ageing. Australian public assessment report for rivaroxaban. September 2012. Available at: www.tga.gov.au/sites/default/files/auspar-rivaroxaban-120913.pdf. Accessed by June 05, 2017.Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447-53. doi: 10.1007/s40261-015-0298-2.Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447-53. doi: 10.1007/s40261-015-0298-2.Brooks KM, Gordon LA, Penzak S, et al. Cobicistat, but not ritonavir, increases dabigatran exposure [Abstract 409]. 2017 Conference on Retroviruses and Opportunistic Infections: Seattle, Washington; February 13-16. Available at: http://www.croiconference.org/sites/default/files/posters-2017/409_Brooks.pdf. Accessed by June 05, 2017.Brooks KM, Gordon LA, Penzak S, et al. Cobicistat, but not ritonavir, increases dabigatran exposure [Abstract 409]. 2017 Conference on Retroviruses and Opportunistic Infections: Seattle, Washington; February 13-16. Available at: http://www.croiconference.org/sites/default/files/posters-2017/409_Brooks.pdf. Accessed by June 05, 2017.Renjifo B, van Wyk J, Salem AH, et al. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015;17(1):37-46. PMID: 25586481.Renjifo B, van Wyk J, Salem AH, et al. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015;17(1):37-46. PMID: 25586481.Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83(2):269-293. doi: 10.1111/bcp.13095.Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83(2):269-293. doi: 10.1111/bcp.13095.Gordon LA, Kumar P, Brooks KM, et al. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers. Circulation. 2016;134(23):1909-11. doi: 10.1161/CIRCULATIONAHA.116.025257.Gordon LA, Kumar P, Brooks KM, et al. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers. Circulation. 2016;134(23):1909-11. doi: 10.1161/CIRCULATIONAHA.116.025257.Yoong D, Naccarato M, Gough K. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir. Ann Pharmacother. 2017; Mar 28 [Epub ahead of print]. doi: 10.1177/1060028017702677.Yoong D, Naccarato M, Gough K. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir. Ann Pharmacother. 2017; Mar 28 [Epub ahead of print]. doi: 10.1177/1060028017702677.Frost C, Shenker A, Gandhi MD, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014;78(4):877-85. doi: 10.1111/bcp.12393.Frost C, Shenker A, Gandhi MD, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014;78(4):877-85. doi: 10.1111/bcp.12393.Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x.Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x.Mendell J, Lee F, Chen S, et al. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62(2):212-21. doi: 10.1097/FJC.0b013e3182970991.Mendell J, Lee F, Chen S, et al. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62(2):212-21. doi: 10.1097/FJC.0b013e3182970991.Stangier J, Stähle H, Rathgen K, et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug. J Thromb Haemost 2007;5(S2):P-T-677. doi: 10.1111/j.1538-7836.2007.tb00029.x.Stangier J, Stähle H, Rathgen K, et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug. J Thromb Haemost 2007;5(S2):P-T-677. doi: 10.1111/j.1538-7836.2007.tb00029.x.Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549-58. doi: 10.1177/0091270006286904.Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549-58. doi: 10.1177/0091270006286904.Upreti VV, Song Y, Wang J, et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol. 2013;5:59-66. doi: 10.2147/CPAA.S41999.Upreti VV, Song Y, Wang J, et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol. 2013;5:59-66. doi: 10.2147/CPAA.S41999.Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555-63. doi: 10.1177/0091270005274550.Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555-63. doi: 10.1177/0091270005274550.Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-95. doi: 10.2165/00003088-200847050-00001.Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-95. doi: 10.2165/00003088-200847050-00001.Moore KT, Plotnikov AN, Thyssen A, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol. 2011;58(6):581-8. doi: 10.1097/FJC.0b013e31822f6c2b.Moore KT, Plotnikov AN, Thyssen A, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol. 2011;58(6):581-8. doi: 10.1097/FJC.0b013e31822f6c2b.FDA Center for Drug Evaluation and Research. Savaysa (edoxaban): Clinical pharmacology & biopharmaceutics review(s). Application No.: 206316Orig1Orig2s000. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf. Accessed by June 05, 2017.FDA Center for Drug Evaluation and Research. Savaysa (edoxaban): Clinical pharmacology & biopharmaceutics review(s). Application No.: 206316Orig1Orig2s000. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf. Accessed by June 05, 2017.Wannhoff A, Weiss KH, Schemmer P, et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation. 2014;98(2):e12-3. doi: 10.1097/TP.0000000000000223.Wannhoff A, Weiss KH, Schemmer P, et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation. 2014;98(2):e12-3. doi: 10.1097/TP.0000000000000223.Hsyu PH, Pignataro DS, Matschke K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol. 2017;73(1):57-63. doi: 10.1007/s00228-016-2115-0.Hsyu PH, Pignataro DS, Matschke K. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol. 2017;73(1):57-63. doi: 10.1007/s00228-016-2115-0.Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19(1):82-93. doi: 10.1634/theoncologist.2013-0239.Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19(1):82-93. doi: 10.1634/theoncologist.2013-0239.

The authors declare that there are no conflicts of interest present.